LGT 209

Drug Profile

LGT 209

Alternative Names: Anti-PCSK9 monoclonal antibody - Novartis; LGT209; NVP-LGT 209

Latest Information Update: 25 Aug 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Novartis
  • Class Antihyperlipidaemics; Monoclonal antibodies
  • Mechanism of Action PCSK9 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Hypercholesterolaemia

Most Recent Events

  • 24 Aug 2016 Cyon Therapeutics in-licenses LGT 209 for the use systemic inflammatory response syndrome and the prevention and treatment of sepsis from Novartis
  • 24 Aug 2016 Cyon Therapeutics plans a phase II trial for Sepsis in
  • 23 Jan 2013 Discontinued - Phase-II for Hypercholesterolaemia in USA (IV, SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top